Duchenne gene therapy late-stage trial fails, Precision gene leader Sarepta (SRPT.US) plunges over 39% in after-hours trading.

Wisdom Financial APP learned that after the late-stage clinical trials of two gene therapies, AMONDYS 45 (casimersen) and VYONDYS 53 (golodirsen), for Duchenne muscular dystrophy (DMD) failed to meet their primary goals, the stock price of global renowned biotech company Sarepta Therapeutics (SRPT.US) focused on rare disease therapy, plummeted significantly, with the stock plunging over 39% in after-hours trading in the US stock market.